Collaboration

Mabion and Oddifact have successfully submitted documentation to the U.S. Food and Drug Administration, including a request for a Type B Pre-IND meeting concerning the MabionCD20 development path in immune thrombocytopenia.

MabionCD20 development path in dialogue with the FDA

Mabion and KriSan Sign Agreement for BIO Asia-Taiwan. Expanding Opportunities for Next-Generation ADC Services.

Mabion and KriSan Biotech sign Agreement to strengthen next-generation ADC services

BIO International 2026 - Mabion Biologics Team

Mabion Biologics at BIO International Convention 2026

Co-development in Biopharma Industry

2026: The Era of Co-development in Biopharma Industry

Analytical Development Project for WPD401

Mabion Completes Analytical Development Project for WPD401

Anna Czubatka-Bieńkowska and Judyta Suskiewicz strengthen strategic biopharma partnerships in Brazil

Strengthening Strategic Biopharma Partnerships in Brazil: Mabion Visits Bio-Manguinhos and IBMP

Inside Mabion’s Transformation Gregor Kawaletz on Scaling, Strategy & Biologic CDMO Ambitions

Executing Mabion’s CDMO Vision: Insights from CEO Gregor Kawaletz

Inside Mabion’s Growth Strategy | CEO Gregor Kawaletz on Biosimilars & Biologics

Gregor Kawaletz featured on Making It in Manufacturing podcast

NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy with Mabion manufacturing capacity.

Mabion Participates in Groundbreaking Clinical Trial of Self-Regulating Immunotherapy